• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • Q&A
    • Videos
    • Comment
    • Analysis
    • People moves
    • In Profile
  •  
    Analysis
    • Videos
    • Q&A
    • Comment
    • In Profile
    • Podcast
    • Fundraising
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Venture

BioMedPartners raises CHF95m for second healthcare venture fund

  • 03 March 2009
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Fund

BioMedPartners has reached a first closing of BioMedInvest II LP on CHF95m, with a target of CHF 120m or more. The fund has a lifespan of ten years with possible extensions. The Guernsey-based fund will remain open for additional new investors for some months. Terms and conditions are described as industry standard. Legal advice was provided by Collas Day.

Investors

The fund is backed by both existing and new investors, including the lead investor ERP-EIF Dachfonds. Further investors include pharmaceutical companies, pension funds and banks, and mainly hail from Germany and Switzerland.

Investments

The fund will invest in early- to later-early-stage private companies and spin-offs in the biotechnology, emerging pharmaceutical, medical technology and other healthcare-related industries such as diagnostics or platform technologies with a geographic focus on Switzerland, Austria, Germany, Italy, Liechtenstein and France. The firm states that these companies offer significant return potential, as large pharma companies are increasingly acquiring biotech firms to fill their product pipelines.

The amount the firm plans to invest over the lifetime of its portfolio companies is about CHF 1-12m and it foresees investing in 15-18 companies over five years. BioMedInvest typically plays the lead or co-lead investor role, structuring the transaction and syndicating with other venture capital firms.

People

Dr Markus Hosang, Dr Gerhard Ries and Thomas Moller are the main managers of the fund and are supported by a team of four investment professionals. BioMedPartners, founded in 2003, has raised over CHF240m until today and invested in more than 25 companies.

Name: BioMedInvest II

Target: CHF 120m

Closed on: CHF 95m

Focus: Early-stage, venture

Contacts: Dr Markus Hosang, Dr Gerhard Ries, Thomas Moller

Address: BioMedPartners

Elisabethenstr. 23

CH-4051 Basel

Tel: +41 61 270 3535

Fax: +41 61 270 3500

Advisers: Collas Day (Legal).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Venture
  • UK / Ireland
  • DACH
  • Nordics
  • France
  • Southern Europe
  • Benelux
  • CEE

More on Venture

Redalpine expands leadership team amid CHF 1bn-plus fundraise
Redalpine expands leadership team amid CHF 1bn-plus fundraise

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • Venture
  • 31 August 2023
VC Profile: RTP Global gears up to deploy largest fund to date, remains bullish on breakout opportunities
VC Profile: RTP Global gears up to deploy largest fund to date, remains bullish on breakout opportunities

Partner Gareth Jefferies discusses early-stage deployment plans and advantages of supporting startups throughout their lifecycle

  • Venture
  • 14 August 2023
Medicxi raises USD 400m to invest in single-focus life sciences companies
Medicxi raises USD 400m to invest in single-focus life sciences companies

GP's fourth fund will deploy USD 10m-USD 20m tickets in narrow indications of unmet need; backed by pharma

  • Venture
  • 27 July 2023
Women in PE: Earth Capital's Bezuidenhoudt and Hockley on 2024 fund launch progress and co-investment pipeline
Women in PE: Earth Capital's Bezuidenhoudt and Hockley on 2024 fund launch progress and co-investment pipeline

UK-based impact investorт€™s female leaders discuss deployment plans and the advantages of its syndicate co-investment strategy

  • Venture
  • 21 July 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013